News

As FDA delays approval, Omaha mom fears son could lose access to experimental drug
"Not approving this medication is a death sentence to not just my son," an Omaha mom told KETV, "but everyone living with" ...
The Manila Times37m
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results ...
CNBCTV1828m
Zydus Life gets tentative USFDA approval for tablets used to treat irritable bowel syndrome
As per the IQVIA data (March, 2025), the Rifaximin tablets had annual sales of $2,672.9 million in the US market.
Zydus Lifesciences gets USFDA nod for Rifaximin tablets
Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin tablets, 550 mg, under the reference listed drug (RLD) ...